首页> 外文期刊>Cell Reports >Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis
【24h】

Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis

机译:组蛋白脱甲基酶RBP2对于乳腺癌进展和转移至关重要

获取原文
           

摘要

Metastasis is a major clinical challenge for cancer treatment. Emerging evidence suggests that aberrant epigenetic modifications contribute significantly to tumor formation and progression. However, the drivers and roles of such epigenetic changes in tumor metastasis are still poorly understood. Using bioinformatic analysis of human breast cancer gene-expression data sets, we identified histone demethylase RBP2 as a putative mediator of metastatic progression. By using both human breast cancer cells and genetically engineered mice, we demonstrated that RBP2 is critical for breast cancer metastasis to the lung in multiple in vivo models. Mechanistically, RBP2 promotes metastasis as a pleiotropic positive regulator of many metastasis genes, including TNC. In addition, RBP2 loss suppresses tumor formation in MMTV-neu transgenic mice. These results suggest that therapeutic targeting of RBP2 is a potential strategy for inhibition of tumor progression and metastasis.
机译:转移是癌症治疗的主要临床挑战。新兴的证据表明,异常的表观遗传修饰对肿瘤形成和进展有显着贡献。然而,肿瘤转移的这种表观遗传变化的司机和作用仍然明白。使用人乳腺癌基因表达数据集的生物信息分析,我们将组蛋白脱甲基酶RBP2鉴定为调用转移性进展。通过使用人类乳腺癌细胞和遗传工程的小鼠,我们证明RBP2对于乳腺癌转移至多个体内模型中的肺部至关重要。机械地,RBP2促进转移作为许多转移基因的磷酸阳性调节剂,包括TNC。此外,RBP2损失抑制MMTV-Neu转基因小鼠中的肿瘤形成。这些结果表明RBP2的治疗靶向是抑制肿瘤进展和转移的潜在策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号